Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Dose-escalating study of the safety and pharmacokinetics of nelfinavir in HIV-exposed neonates.

Rongkavilit C, van Heeswijk RP, Limpongsanurak S, Thaithumyanon P, Boonrod C, Hassink EA, Srigritsanapol A, Chuenyam T, Ubolyam S, Hoetelmans RM, Ruxrungtham K, Lange JM, Cooper DA, Phanuphak P.

J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):455-63.

PMID:
11981361
2.

Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study).

Pellegrin I, Breilh D, Montestruc F, Caumont A, Garrigue I, Morlat P, Le Camus C, Saux MC, Fleury HJ, Pellegrin JL.

AIDS. 2002 Jul 5;16(10):1331-40.

PMID:
12131209
3.

The pharmacokinetics of combination therapy with nelfinavir plus nevirapine.

Merry C, Barry MG, Mulcahy F, Ryan M, Tjia JF, Halifax KL, Breckenridge AM, Back DJ.

AIDS. 1998 Jul 9;12(10):1163-7.

PMID:
9677165
5.

Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403.

King JR, Nachman S, Yogev R, Hodge J, Aldrovandi G, Hughes MD, Chen J, Wiznia A, Damle B, Acosta EP.

Pediatr Infect Dis J. 2005 Oct;24(10):880-5.

PMID:
16220085
6.

Pharmacokinetic evaluation and short-term activity of stavudine, nevirapine, and nelfinavir therapy in HIV-1-infected adults.

Skowron G, Leoung G, Hall DB, Robinson P, Lewis R, Grosso R, Jacobs M, Kerr B, MacGregor T, Stevens M, Fisher A, Odgen R, Yen-Lieberman B.

J Acquir Immune Defic Syndr. 2004 Apr 1;35(4):351-8.

PMID:
15097151
7.

Pharmacokinetics of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1.

Litalien C, Faye A, Compagnucci A, Giaquinto C, Harper L, Gibb DM, Jacqz-Aigrain E; Paediatric European Network for Treatment of AIDS Executive Committee..

Pediatr Infect Dis J. 2003 Jan;22(1):48-55.

PMID:
12544409
8.

SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients.

Gathe JC Jr, Ive P, Wood R, Schürmann D, Bellos NC, DeJesus E, Gladysz A, Garris C, Yeo J.

AIDS. 2004 Jul 23;18(11):1529-37.

PMID:
15238771
9.

A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity.

Kumar PN, Rodriguez-French A, Thompson MA, Tashima KT, Averitt D, Wannamaker PG, Williams VC, Shaefer MS, Pakes GE, Pappa KA; ESS40002 Study Team..

HIV Med. 2006 Mar;7(2):85-98.

10.
11.

The pharmacokinetics of nelfinavir in HIV-1-infected children.

van Heeswijk RP, Scherpbier HJ, de Koning LA, Heymans HS, Lange JM, Beijnen JH, Hoetelmans RM.

Ther Drug Monit. 2002 Aug;24(4):487-91.

PMID:
12142631
12.

Pharmacokinetics of nelfinavir in children: influencing factors and dose implications.

Bergshoeff AS, Fraaij PL, van Rossum AM, Wolfs TF, Geelen SP, de Groot R, Burger DM.

Antivir Ther. 2003 Jun;8(3):215-22.

PMID:
12924538
13.

Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study.

Cardiello PG, van Heeswijk RP, Hassink EA, Srasuebkul P, Mahanontharit A, Samor TM, Worarien W, Beijnen JH, Hoetelmans RM, Ruxrungtham K, Cooper DA, Lange JM, Phanuphak P.

J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):464-70.

PMID:
11981362
14.

Efavirenz, nelfinavir, and stavudine rescue combination therapy in HIV-1-positive patients heavily pretreated with nucleoside analogues and protease inhibitors.

Seminari E, Maggiolo F, Villani P, Suter F, Pan A, Regazzi MB, Paolucci S, Baldanti F, Tinelli C, Maserati R.

J Acquir Immune Defic Syndr. 1999 Dec 15;22(5):453-60. Erratum in: J Acquir Immune Defic Syndr 2000 Mar 1;23(3):278.

PMID:
10961606
15.

Nelfinavir pharmacokinetics in stable human immunodeficiency virus-positive children: Pediatric AIDS Clinical Trials Group Protocol 377.

Floren LC, Wiznia A, Hayashi S, Jayewardene A, Stanley K, Johnson G, Nachman S, Krogstad P, Aweeka FT; Pediatric AIDS Clinical Trials Group 377 Protocol Team..

Pediatrics. 2003 Sep;112(3 Pt 1):e220-7.

PMID:
12949316
16.

Pharmacokinetics of nelfinavir in human immunodeficiency virus-infected infants.

Capparelli EV, Sullivan JL, Mofenson L, Smith E, Graham B, Britto P, Becker MI, Holland D, Connor JD, Luzuriaga K; Pediatric ACTG 356 Investigators..

Pediatr Infect Dis J. 2001 Aug;20(8):746-51.

PMID:
11734735
17.

Effect of antiretroviral triple combinations including the protease inhibitor nelfinavir in heavily pretreated children with HIV-1 infection.

Hoffmann F, Funk M, Linde R, Notheis G, Petropoulou T, Eberle J, Gürtler L, Belohradsky BH, Wintergerst U.

Eur J Med Res. 2002 Jul 24;7(7):330-4.

PMID:
12176683
18.

Pharmacokinetics of stavudine and didanosine coadministered with nelfinavir in human immunodeficiency virus-exposed neonates.

Rongkavilit C, Thaithumyanon P, Chuenyam T, Damle BD, Limpongsanurak S, Boonrod C, Srigritsanapol A, Hassink EA, Hoetelmans RM, Cooper DA, Lange JM, Ruxrungtham K, Phanuphak P.

Antimicrob Agents Chemother. 2001 Dec;45(12):3585-90.

19.

Primary nelfinavir (NFV)-associated resistance mutations during a follow-up period of 108 weeks in protease inhibitor naïve patients treated with NFV-containing regimens in an HIV clinic cohort.

Tsuchiya K, Matsuoka-Aizawa S, Yasuoka A, Kikuchi Y, Tachikawa N, Genka I, Teruya K, Kimura S, Oka S.

J Clin Virol. 2003 Aug;27(3):252-62.

PMID:
12878089
20.

Population pharmacokinetics and pharmacodynamics of nelfinavir and its active metabolite M8 in HIV-1-infected children.

Crommentuyn KM, Scherpbier HJ, Kuijpers TW, Mathôt RA, Huitema AD, Beijnen JH.

Pediatr Infect Dis J. 2006 Jun;25(6):538-43.

PMID:
16732153

Supplemental Content

Support Center